Vertex Pharmaceuticals (VRTX) Other Gross PP&E Adjustments (2009 - 2026)

Vertex Pharmaceuticals' Other Gross PP&E Adjustments history runs 18 years deep, the most recent figure standing at -$1.7 billion for Q1 2026.

• On a quarterly basis, Other Gross PP&E Adjustments fell 25.89% year-over-year to -$1.7 billion in Q1 2026; TTM through Mar 2026 was -$1.7 billion, a 25.89% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 49.58% from the prior year.
• Other Gross PP&E Adjustments eased to -$1.7 billion in Q1 2026 per VRTX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Other Gross PP&E Adjustments topped out at $2.2 billion in Q4 2024 and bottomed at -$1.7 billion in Q1 2026.
• The 5-year median for Other Gross PP&E Adjustments is -$329.0 million (2022), against an average of -$185.8 million.
• Across the five-year window, Other Gross PP&E Adjustments grew 14.16% in 2023 and slumped 349.63% in 2024, its largest moves.
• Year by year, Other Gross PP&E Adjustments stood at $1.7 billion in 2022, then gained by 14.16% to $2.0 billion in 2023, then rose by 8.84% to $2.2 billion in 2024, then sank by 49.58% to $1.1 billion in 2025, then slumped by 253.88% to -$1.7 billion in 2026.
• Per Business Quant, the three latest VRTX Other Gross PP&E Adjustments figures stand at -$1.7 billion (Q1 2026), $1.1 billion (Q4 2025), and -$1.6 billion (Q3 2025).